{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-007080","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.685297+00:00","generated_at":"2026-05-26T17:40:31.042358+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Telomir-1 reduces oxidative stress in human retinal cells, advancing potential AMD treatment","bullets":["Telomir-1 significantly reduced reactive oxygen species (ROS) elevation from copper and iron exposure in human retinal cell lines.","Compound showed strong ROS regulation at low concentrations, suggesting a regulatory effect beyond metal chelation.","Study targets age-related macular degeneration (AMD) and other retinal diseases linked to oxidative stress.","Company initiating AMD disease models to evaluate in vivo efficacy and support potential clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-007080","json":"https://secwatch.observer/filing/0001493152-25-007080.json","markdown":"https://secwatch.observer/filing/0001493152-25-007080.md","text":"https://secwatch.observer/filing/0001493152-25-007080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225007080/0001493152-25-007080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225007080/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T17:40:31.042358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}